TrialThe Indian journal of medical research2026
Saroglitazar for non-obese metabolic-dysfunction associated steatotic liver disease (MASLD): An open-label randomised controlled trial.
Naveen Bhagat et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.